What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Cancer
- Surgery
His primary scientific interests are in Internal medicine, Renal cell carcinoma, Surgery, Carcinoma and Oncology.
His research on Internal medicine often connects related topics like Gastroenterology.
His Renal cell carcinoma research includes themes of Survival rate, Everolimus, Nephrectomy and Phases of clinical research.
His Surgery research focuses on Hazard ratio and how it connects with Proportional hazards model.
His Carcinoma research is multidisciplinary, incorporating elements of Clinical trial, Tolerability, Adverse effect, Immunology and Survival analysis.
His Oncology research also works with subjects such as
- Biomarker most often made with reference to Pathology,
- Retrospective cohort study which connect with Mortality rate.
His most cited work include:
- Sorafenib in advanced clear-cell renal-cell carcinoma. (4025 citations)
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma (3172 citations)
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial (2410 citations)
What are the main themes of his work throughout his whole career to date?
The scientist’s investigation covers issues in Internal medicine, Renal cell carcinoma, Oncology, Sunitinib and Surgery.
His work on Sorafenib, Cancer, Everolimus and Bevacizumab as part of his general Internal medicine study is frequently connected to In patient, thereby bridging the divide between different branches of science.
Bernard Escudier interconnects Hazard ratio, Nivolumab, Carcinoma and Clinical trial in the investigation of issues within Renal cell carcinoma.
His Oncology research integrates issues from Targeted therapy, Adverse effect and Proportional hazards model.
His Sunitinib research incorporates elements of Temsirolimus, Progression-free survival, Phases of clinical research and Urology.
His Surgery study combines topics from a wide range of disciplines, such as Gastroenterology and Nephrectomy.
He most often published in these fields:
- Internal medicine (65.14%)
- Renal cell carcinoma (56.76%)
- Oncology (53.92%)
What were the highlights of his more recent work (between 2017-2021)?
- Renal cell carcinoma (56.76%)
- Internal medicine (65.14%)
- Oncology (53.92%)
In recent papers he was focusing on the following fields of study:
The scientist’s investigation covers issues in Renal cell carcinoma, Internal medicine, Oncology, Sunitinib and Nivolumab.
His Renal cell carcinoma study combines topics in areas such as Carcinoma, Sorafenib and Hazard ratio.
His Carcinoma research incorporates themes from Vascular endothelial growth factor and Survival analysis.
His work carried out in the field of Oncology brings together such families of science as Phases of clinical research and Immunotherapy.
His research integrates issues of Bevacizumab, Adjuvant, Randomized controlled trial and Urology in his study of Sunitinib.
Bernard Escudier has included themes like Cell, Ipilimumab and Immune checkpoint inhibitors in his Nivolumab study.
Between 2017 and 2021, his most popular works were:
- Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma (1476 citations)
- Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma (385 citations)
- Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial (302 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Cancer
- Surgery
His scientific interests lie mostly in Renal cell carcinoma, Internal medicine, Oncology, Sunitinib and Nivolumab.
His Renal cell carcinoma study integrates concerns from other disciplines, such as Carcinoma, Everolimus, Phases of clinical research and Urology.
His work deals with themes such as Survival rate, Cancer, Sorafenib and Subgroup analysis, which intersect with Oncology.
The concepts of his Sunitinib study are interwoven with issues in Bevacizumab, Risk groups, Atezolizumab and Proportional hazards model.
His study looks at the intersection of Proportional hazards model and topics like Nephrectomy with Primary outcome, Renal function, Neoadjuvant treatment, Surgery and Axitinib.
Bernard Escudier has researched Nivolumab in several fields, including Immune checkpoint, Adverse effect, Ipilimumab and Clear cell.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
